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Edited by Shou-Wei DingAbstract Successful applications of RNAi in mammalian cells
depend upon eﬀective knockdown of targeted transcripts and eﬃ-
cient intracellular delivery of either preformed si/shRNAs or vec-
tor expressed si/shRNAs. We have previously demonstrated that
27 base pair double stranded RNAs which are substrates for Di-
cer can be up to 100 times more potent than 21mer siRNAs. In
this mini-review we elaborate upon the rationale and design
strategies for creating Dicer substrate RNAs that provide en-
hanced knockdown of targeted RNAs and minimize the utiliza-
tion of the sense strand as RNAi eﬀectors. Expression of
shRNAs or siRNAs in mammalian cells can be achieved via tran-
scription from either Pol II or Pol III promoters. There are cer-
tain constrictions in designing such vectors, and these are
described here. Additionally, we review strategies for inducible
shRNA expression and the various viral vectors that can be used
to transduce shRNA genes into a variety of cells and tissues. The
overall goal of this mini-review is to provide an overview of avail-
able approaches for optimizing RNAi mediated down regulation
of gene expression in mammalian cells via RNA interference.
Although the primary focus is the use of RNAi mediated cleav-
age of targeted transcripts, it is highly probable that some of
the approaches described herein will be applicable to RNAi med-
iated inhibition of translation and transcriptional gene silencing.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNA interference (RNAi) is a process, ﬁrst described in the
worm Caenorhabditis elegans, whereby the presence or intro-
duction of long double-stranded RNA (dsRNA) in cells results
in the degradation of homologous mRNA [1,2]. Long dsRNA
is processed to 21–23 bp short interfering RNA (siRNA) with 2
nt 3 0 overhangs by the RNAseIII-like protein Dicer [3]. These
cleavage products are subsequently incorporated into the
RNA-induced silencing complex (RISC) [4]. Delivery of chem-
ically synthesized short interfering RNAs, mimicking Dicer
cleavage substrates, results in sequence-speciﬁc, robust silenc-
ing of the expression of the corresponding endogenous gene
[5], thus bypassing the non-speciﬁc inhibitory mechanisms elic-
ited by longer dsRNA inmammalian cells [6]. RNAi can also be*Corresponding author.
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(shRNAs) [7]. shRNAs are structurally related to a highly con-
served class of small RNAs known as microRNAs (miRNAs)
that mediate RNAi through a translational inihibition mecha-
nism involving imperfect complementarity to sites in the 3 0
UTR of target genes [8]. miRNAs are transcribed as precursors
that are ﬁrst processed in the nucleus by the RNaseIII protein
Drosha in the Microprocessor complex [9–11]. The product of
Drosha-mediated processing, pre-miRNA, is exported to the
cytoplasm by Exportin 5 [12], for further processing by Dicer
to the mature miRNA [13]. One of the strands is incorporated
into a RISC-like silencing complex [14].
RNAi has recently become the method of choice for mam-
malian cell genetic analysis and has the potential to serve as
a therapeutic treatment for a variety of acquired and heredi-
tary diseases [15]. In this review, we will describe the various
methodologies for eliciting RNAi by either synthetic or ex-
pressed RNAi eﬀector molecules.2. Synthetic siRNA-mediated RNAi
2.1. Enzymatically generated siRNA
The most cost eﬀective and quickest method for siRNA syn-
thesis is T7 phage RNA polymerase mediated in vitro transcrip-
tion from short double-stranded oligo cassettes containing the
promoter sequence immediately upstream of the siRNA strand
template sequence to be transcribed [16,17]. The siRNA strands
are synthesized in separate reactions and hybridized before
puriﬁcation. Once the template oligos are available, template
preparation (annealing), in vitro transcription, siRNA anneal-
ing, and puriﬁcation can be completed within 24 h. The siRNAs
synthesized by this method frequently contain a GGG leader
sequence (deriving from the promoter) as well as a 5 0 triphos-
phate group [18]. The hybridized siRNA thus needs to be pro-
cessed by T1 ribonuclease to remove the single stranded 5 0
GGG overhang. If the siRNAs are transcribed with UU 3 0
overhangs, T1 processing may be incomplete due to the poten-
tial formation of two G:U wobble base pairs with the Gs of the
5 0 leader sequence. Incomplete processing will result in reten-
tion of transcripts with 5 0 triphosphate groups, which triggers
non-speciﬁc inhibition of gene expression through the inter-
feron pathway [18]. Although we have shown that the inter-
feron response and RNAi are independent pathways [18],
these siRNAs should be used with great caution in applications
related to viral infection or innate immune responses. This ap-
proach may therefore be more appropriate for initial screening
of target sites prior to validation of any results by chemicallyblished by Elsevier B.V. All rights reserved.
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3 0AA that cannot form wobble base pairs with the 5 0GG im-
proves processing and reduces the potential for interferon
induction [18]. Changing the siRNA from 19 + UU to
21 + AA, with a 21 nt target complementary duplex region
was also associated with enhanced RNAi activity.
Diﬀerent siRNA sequences display widely diﬀering eﬃcacies,
requiring screening of multiple sequences [19–21]. One way to
get around this problem is by application of a pool of enzymat-
ically generated siRNAs. Dicer, an RNase III family enzyme,
cleaves in vitro transcribed long dsRNA into a pool of siRNAs
suitable for gene silencing [22]. Therefore, several groups have
produced a recombinant version of Dicer and used it to digest
in vitro transcribed dsRNAs into a complex pool of siRNAs
(d-siRNA) [23]. Nearly every pool of d-siRNAs is capable of
eliciting speciﬁc gene silencing. This approach eliminates the
need to identify an individual eﬀective siRNA and has proven
to be useful for transiently silencing many endogenous genes in
several types of cells. Although the method is eﬃcacious, cost
eﬀective, and relatively quick, there are some potential prob-
lems. Any residual unprocessed long dsRNA will activate
RNA-dependent protein kinase (PKR), resulting in non-spe-
ciﬁc translational inhibition [6]. Gel puriﬁcation of 21–23mer
siRNAs from unprocessed long dsRNAs and partially pro-
cessed products is therefore essential before transfection of
siRNAs into cells. Additional concerns associated with the
use of pools of siRNAs are the potential increased oﬀ-target
eﬀects occasionally observed with siRNA [24]. Competition
from less eﬃcacious siRNAs in a pool may also reduce the
overall eﬃcacy compared to utilization of one optimal siRNA
sequence. A further advantage of utilizing one siRNA of
known sequence is that any observed phenotypes of the siRNA
can be veriﬁed through the application of a second siRNA spe-
cies targeting the same gene. The siRNA pool approach may
require additional conﬁrmation through the use of target-spe-
ciﬁc and mismatched siRNA of deﬁned sequence to verify the
sequence speciﬁcity of the observed phenotype.2.2. Chemically synthesized siRNAs
Chemically synthesized siRNAs represent the gold standard
for RNAi applications. They are of a uniform composition
and can be synthesized at higher amounts and with a wider
range of chemical modiﬁcations than by other methods [25–
27]. The disadvantages include higher cost and increased syn-
thesis time. Initial studies in Drosophila melanogaster embryo
lysates concluded that 21 nt siRNAs with 2 nt 3 0 overhangs
were the most eﬃcient triggers of sequence-speciﬁc mRNA
degradation [28], and most subsequent studies have therefore
employed this format. During investigation of cellular inter-
feron induction caused by in vitro transcribed siRNAs, we ob-
served that some siRNAs of length 25–27 appeared to have
greater potency than synthetic 21mer siRNAs directed to the
same target site [18]. Synthetic RNA duplexes of varying
length containing 3 0-overhangs, 5 0-overhangs, or blunt ends,
were tested for their relative potency in several reporter sys-
tems [29]. Using duplex RNA at several concentrations, we ob-
served that potency increased with length up to a duplex length
of 27 bp. Increased potency was observed even for siRNAs
with 5 0 overhangs or blunt ends [29]. Reduced eﬃcacy was ob-
served for siRNA with longer than 27 bp stems, which also
exhibited slower in vitro Dicing kinetics. Importantly, the27mers do not induce interferon or activate PKR. Hannon
and colleagues [30] also found synthetic shRNAs with 29-
base-pair stems and 2-nucleotide 3 0 overhangs to be more
potent inducers of RNAi than shorter hairpins. Maximal inhibi-
tion of target genes was achieved at lower concentrations and
silencing persisted longer. The improved eﬃcacies of the longer
forms of siRNA, termed ‘‘disRNAs’’ or ‘‘Dicer-substrate siR-
NAs’’, is postulated to result from their recognition and cleav-
age by Dicer, followed by their subsequently more eﬃcient
incorporation into the RISC complex. This interpretation is
supported by observations that Drosophila Dicer is not only
instrumental in handing over siRNA to nascent RISC, but is
itself a component of the latter [31,32]. Providing the RNAi
machinery with a Dicer substrate therefore presumably results
in more eﬃcient incorporation of the active 21mer into RISC.
DisRNAs have subsequently been successfully employed by
others [33].
Further investigation determined that the eﬃcacy of dsiR-
NAs varies with the target (Kim et al., unpublished data).
One reason for this is that multiple 21mer siRNAs of poten-
tially highly variable activity can result from the same 27mer
after processing by Dicer. We investigated this possibility by
electrospray ionization mass spectrometry (ESI MS) analysis
of in vitro diced dsiRNA. As expected, multiple 21–22mer
products were generated from the dicing reactions. Optimal
design of Dicer substrate siRNAs thus requires the ability to
either predict the resulting 21mer(s) or direct cleavage to gen-
erate only a desired 21mer. The natural role of Dicer in cells
appears to be ﬁnalizing the processing of miRNA [13], a highly
conserved class of small RNAs that function in the regulation
of expression of a wide range of genes at the translational level
[34]. The substrates of Dicer, pre-miRNA, are bulged stem-
loop structures with 2 nt 3 0 overhangs, and recent reports sug-
gest that the overhangs in the open end of the stem in such
structures are bound by Dicer and determine the direction of
processing [30]. The miRNA strand harboring the 3 0 overhang
is utilized more frequently than the top strand [35]. In an at-
tempt to introduce a similar directionality into disRNA, we
developed a format of 27mer (25/27R) in which the top strand
is 25mer, and the bottom strand a 27mer with 2 nt overhangs
in 3 0 end. This reduced the complexity of dicing products but
did not result in a single product. Further investigations
determined that incorporation of DNA nucleotides in the 3 0
end of the top strand (near the blunt end of the duplex) re-
sulted in processing proceeding exclusively from the overhang
end, producing a single primary 21mer siRNA of predictable
sequence (Fig. 1). It is therefore possible to design a disRNA
that is processed by Dicer to yield a speciﬁc, desired 21mer spe-
cies. The same 21mer could be generated from a disRNA of
slightly diﬀerent sequence in which the top strand is 27mer
with 2 nt overhangs in the 3 0 end, while the bottom strand is
a 25mer (27/25L), and the DNA nucleotides were introduced
in the bottom strand near the blunt end. The 25/27R is pro-
cessed to the 3 0 end (right direction) and produces one major
21mer (R form). The 27/25mer is processed in the left direction
and produces the same 21mer (L form). Interestingly, the ‘‘R’’
versions of the asymmetric 27mers were consistently more eﬃ-
cacious than the ‘‘L’’ versions (Fig. 1). This diﬀerence in po-
tency of disRNA producing the same 21mer duplex
suggested to us the possibility that Dicer processing may intro-
duce some asymmetry in strand incorporation into RISC
through preferential binding to the 30 overhang. RISC-mediated
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Fig. 1. Suppression of EGFP ﬂuorescence by RNA duplexes. Top: an EGFP expression plasmid was transfected into cells with an irrelevant (con) or
the indicated siRNA at 500 pM and EGFP ﬂuorescence measured 48 hours post-transfection. Bottom: EGFP target sequence (S strand) is shown and
duplexes employed in transfections are aligned beneath in duplex form with S strand top (5 0 ﬁ 3 0) and AS strand bottom (3 0 ﬁ 5 0). RNA bases are
upper case, DNA bases are lower case bold.
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unwinding of the siRNA and loss of one of the strands [36],
in a process probably mediated by an RNAi-associated heli-
case [37]. Results from Zamores group indicate that the se-
quence and structure of siRNA determines which of two
strands enters RISC (the guide strand) and which is excluded
(the passenger strand) [38]. By taking advantage of this func-
tional asymmetry, one can design siRNA with improved eﬃ-
cacy and reduced passenger strand-mediated oﬀ-target
eﬀects. We proposed that a similar mechanism could explain
the diﬀerential potencies of R and L form disRNAs. Thus,
even though the same 21mers are produced, 25/27R would fa-
vor incorporation of the bottom (guide) strand, while 27/25L
would favor top (passenger) strand incorporation. One predic-
tion of this postulate is that the L-form disRNA would target
an antisense transcript more eﬃciently than the R form. We
decided to test this by generating two reporter constructs in
which the same cDNA fragments were cloned in two diﬀerent
orientations in the same position within the 3 0 UTR of the Re-
nilla luciferase gene, in the psiCheck2 vector (Promega)
(Fig. 2). Cotransfection experiments determined that, for two
diﬀerent target genes, the L form did indeed target the anti-
sense transcript more eﬃciently than the R form (Fig. 2). In
conclusion, the new asymmetrical disRNA format results in
21mers of predictable sequence, superior potency, and reduced
potential for passenger strand mediated oﬀ-target eﬀects,
through Dicer-dependent preferential incorporation of the
guide strand into RISC.3. Vector-based RNAi
Downregulation of gene expression mediated by siRNA is
transient, and frequently lasts for only 3–5 days in cell culture
[20]. While this may be suﬃcient for many applications, for
studies of proteins with long half-lives, a single transfection
of siRNA may not provide a suﬃcient window of functional
depletion. Another potential problem inherent in transient
transfection of siRNA for functional genomics studies is vari-
ability in transfection eﬃciency. This is of particular concern
when working with diﬃcult-to-transfect cell lines. The solution
to this problem is stable expression of RNAi eﬀector molecules
from plasmids or viral vectors. The use of viral vectors, such as
lentiviruses and adenovirus [39–43], allows easy generation of
transgenics of even hard-to-transfect cells. Vector-based RNAi
also permits co-expression of reporter genes such as GFP or
luciferase, which facilitates tracking and/or selection/enrich-
ment of transfected/transduced cells. Three diﬀerent strategies
exist for vector-based RNAi, involving the expression of mol-
ecules that can be classiﬁed as shRNA, siRNA and miRNA
(Table 1). The most commonly used approach involves RNA
polymerase III-mediated transcription of short hairpin struc-
tures with a stem of 19–29 bp and a short loop of 4–10 nt
[7,44,45] (Fig. 3A). Less commonly, the two strands of an siR-
NA are transcribed from separate expression units, from either
the same or two separate plasmids [46,47] (Fig. 3B). Finally,
the eﬀector molecules may be expressed as a chimera of siRNA
and miRNA [48] (Fig. 3C).
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Fig. 2. Strand bias is introduced by the direction of Dicer processing. Top: Luciferase reporter constructs containing a fragment of hnRNPH coding
sequence cloned into the 3 0-UTR in both ‘‘S’’ and ‘‘AS’’ orientations were transfected into cells with irrelevant (con) or indicated target-speciﬁc
siRNA at 0.4 or 2 nM concentration and dual luciferase activity determined 26 hours post-transfection. Relative expression levels were normalized to
levels in control-transfected cells. Bottom: Luciferase reporter constructs containing a fragment of hnRNPH coding sequence cloned into the 3 0-UTR
of Renilla luciferase of the dual luciferase psiCheck2 vector in both ‘‘S’’ and ‘‘AS’’ orientations.
able 1
xpression systems for vector-based RNAi
xpression unit Promoter Inducible system Refs.
himeric miRNA CMV Not inducible [48,52,53]
RNA-shRNA
usion
tRNA-Val Not inducible [54]
hRNA U6 Not inducible [45,56]
Tetracycline [57,68,69]
Ecdysone [73]
Cre-loxP [74–77,79,80]
H1 Not inducible [7]
Tetracycline [60]
Lac [70]
7SK Not inducible [57]
Tetracycline [57]
iRNA U6 Not inducible [46,47]
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Expression of an shRNA as part of a longer polymerase II
derived transcript faces the problem that extraneous sequences
might render the heterogeneous transcripts unrecognizable by
the cellular RNAi machinery [45]. This is not surprising since
near-perfect stem-loop structures are not uncommon in natu-
rally occurring mRNAs, yet do not appear to be processed
to siRNA-like molecules. The expression of RNAi eﬀectors
as part of more complex transcripts therefore needs to address
the problem of proper processing, which may be achievedthrough incorporation in the primary transcript of naturally
occurring signal sequences to direct their processing. Such a
strategy is used for expression of siRNA as a part of a poly-
merase II miRNA transcript. miRNAs are structurally very
similar to siRNAs and are incorporated into a RISC-like com-
plex that shares many of the same components as RISC [14].
Silencing by miRNA occurs at the translational level through
imperfect mismatches with the target [49,50]. When the target
is perfectly complementary, however, miRNAs can mediate
cleavage [51]. Mature miRNAs can be generated from RNA
polymerase II transcribed mRNAs containing irrelevant se-
quences in addition to the predicted pre-miRNA precursor se-
quence [48,52]. While production of mature miRNA requires
maintaining the proper precursor stem-loop structure, the
exact sequence of this precursor does not appear to be impor-
tant, and can therefore be replaced with a heterologous stem
(Fig. 3C), enabling the generation of a miRNA-based expres-
sion cassette with generalizable targeting properties. Recent
work suggests that single stranded extensions to the pre-miR-
NA hairpin structure are required for full Drosha functionality
[53]. Therefore, to ensure that heterologous miRNAs are prop-
erly processed, miRNA-based expression cassettes should, in
addition to the pre-miRNA structure, contain 5 0 and 3 0 exten-
sions derived from the wild-type miRNA gene to mimic the
structure of the wildtype transcript as closely as possible.
Another enticing possibility is the expression of shRNA as a
3 0 fusion with a tRNA to allow eﬃcient cytoplasmic delivery
while supporting the eventual removal of the tRNA compo-
nent. A fusion construct between tRNAVal and an shRNA
with a 30 bp stem has been reported to support RNAi [54],
but is it unclear whether the chimeric transcript is transported
Fig. 3. Schematic representation of expression cassettes for shRNA (A), siRNA (B) and miRNA (C). PIII(U6): pol III promoter (U6), PCMV: pol II
promoter (CMV), S: siRNA sense strand, AS: siRNA antisense strand, L: loop, T: terminator, 5 0mi: 5 0 pri-miRNA sequence, 3 0mi: 3 0 pri-miRNA,
ext: extraneous transcript sequences. The 5 0mi and 3 0mi sequences direct proper excision of the siRNA from the heterologous transcript.
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general utility of this approach for expression and cytoplasmic
delivery of siRNA, and its potential advantages over other,
simpler modes of expression, are however still open questions.
Nevertheless, the recent report that a predicted virus-encoded
miRNA appears to be expressed as a tRNA fusion transcript
[55], validates the potential utility of this approach.
Due to the various limitations associated with the expression
of RNAi eﬀectors as parts of larger transcripts, the most com-
mon strategies for vector-based RNAi involve the use of
self-contained RNA polymerase III promoters. shRNA and
siRNA are commonly expressed from U6 [45,47,56], H1 [7]
or 7SK [57] promoters. Transcription is initiated at a precise
position outside of the promoter sequence and terminates
upon encountering a stretch of 4–6 thymidines in the expres-
sion cassette. Thus, for expression of an shRNA, an expression
cassette encoding, in the following order, the top strand of the
hairpin, the hairpin loop, the bottom strand of the hairpin, and
the terminator, is inserted immediately downstream of the pro-
moter, by various means (Fig. 3A). For expression of siRNA,
two separate cassettes consisting of the promoter, the top or
bottom strand and the terminator have to be generated
(Fig. 3B). Previous experiences from expression of ribozymes
suggest that heterogeneity in the 3 0 overhang of the transcribed
shRNA may be generated, either through imprecise termina-
tion or the action of 3 0 exonucleases following termination
after the fourth U in the terminator [58]. This variability is
however not likely to be of signiﬁcant practical importance
for the eﬃcacy of the siRNAs or shRNAs, as short 3 0 over-
hangs of variable length appear to be well tolerated within
both types of molecules [28,59].
3.2. Practical considerations for construction of polymerase
III-based RNAi vectors
Two principle methods for generating siRNA/shRNAs
expression cassettes exist, each with its own advantages and
drawbacks. In the ﬁrst method, the cassette is generated by
annealing of two complementary oligos, generating a double-
stranded oligo cassette with appropriate overhangs for direc-
tional cloning downstream of the promoter. This methodology
is straightforward and eﬃcient, but the overhang sequences
that are used for cloning will result in expression of an shRNA
with a 5 0 leader sequence if the restriction site in the vector that
is used for cloning is outside of the promoter. Such a leader se-
quence is likely to aﬀect the potency of the transcribed siRNA.
This problem can be avoided by inserting the cloning site with-
in the 3 0 end of the promoter, covering positions 5 to +1 rel-
ative to the transcription start site (+1), so that the overhangfrom the oligo cassette will be part of the promoter proper
(covering positions 4 to 1), while transcription starts at
the ﬁrst position in the double-stranded part of the oligo cas-
sette, encoding the eﬀector molecule. This strategy requires
mutating the wild-type promoters to introduce a suitable clon-
ing site. Targeted mutations within U6 and H1 promoters to
introduce a BglII site have been shown to be compatible with
eﬀective transcription and shRNA-mediated silencing of
expression [60] (Amarzguioui et al., unpublished data). An
alternative but more cumbersome methodology, that avoids
a leader sequence while retaining the wild-type promoter se-
quence, requires cloning of an oligo cassette with a blunt 5 0
end into a recessed restriction site immediately after the pro-
moter [47]. In addition to the oligo cassette-based cloning
strategies, a PCR-based cloning strategy is also commonly em-
ployed [61]. A PCR product containing the promoter and the
sequences encoding the shRNA or siRNA is ampliﬁed using a
5 0 promoter primer in combination with a tagged 3 0 promoter
primer in which the tag consists of the reverse complement of
the expression unit. This method has the advantage that the
resulting PCR products support expression of siRNA or
shRNA when transfected directly into cells, and the approach
is therefore useful for screening of multiple constructs for eﬃ-
cacy [61]. However, in our experience, this approach is gener-
ally associated with a higher degree of deletion mutants,
requiring more extensive screening of resulting clones.
3.3. RNAi eﬀector molecule design
Due to the sequence-dependent variability of siRNA eﬃcacy
[20,62], design of the eﬀector molecules is an important factor
to consider. Statistical analyses of increasingly larger groups of
sequences have however resulted in the identiﬁcation of design
rules that substantially improve the frequency of functional
siRNA [38,62–64]. The single most important determinant of
siRNA eﬃcacy appears to be an asymmetry in duplex end sta-
bility that mirrors that observed for naturally occurring miR-
NAs and which inﬂuences asymmetrical strand incorporation
into RISC [38]. Additional position-speciﬁc determinants of
unknown function [63,64], as well as target secondary structure
[65], also appear to contribute to overall siRNA eﬃcacy.
Although a large-scale statistical analysis of factors aﬀecting
shRNA eﬃcacy have not yet been published, limited compar-
isons of siRNA and shRNA targeting the same sites suggest a
similar degree of eﬃcacy and sequence-dependence. The avail-
able evidence thus suggests that shRNA design may be based
on the design rules for siRNA. In the case of U6-based expres-
sion platforms, the presence of a G at the transcription start
position is highly recommended. This does, however, not rep-
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sense strand of siRNA (the ﬁrst transcribed nucleotide) is pos-
itively correlated with siRNA functionality [64].
Most design rules for siRNA have been based on duplexes of
19 bp with 2 nt 3 0 overhangs, while the stems of expressed shR-
NAs range in size from 19 to 29 bp [7,44,45]. Early reports sug-
gested that longer stems were generally more favorable than
shorter ones [45]. A recent report analyzing the in vitro Dicer
processing pattern of shRNA of various stem lengths largely
conﬁrm previous conclusions [30]. The results from these stud-
ies indicate that cleavage of the duplex occurs in a precise man-
ner 21–22 nt from the open end of the stem. Hairpins of
diﬀerent lengths with extension of the duplex towards the loop
would thus be expected to generate the same processed prod-
uct, and any diﬀerences in eﬃcacy between the precursor hair-
pins should reﬂect diﬀerences in either Dicer-mediated
processing or cytoplasmic transport of the precursor. While
diﬀerential transport eﬃciency cannot be discounted, the re-
cent observations that asymmetrical siRNA of extended stems
display similar improvements in eﬃcacy as shRNA [29,66],
suggest that enhanced Dicer-mediated processing contributes
chieﬂy to this improvement. Furthermore, Dicer processing
appears to also confer an asymmetry in strand incorporation
into RISC, as the strand bearing the 3 0 overhang (the bottom
strand in an expressed hairpin) is utilized preferentially [66].
The above combined data thus suggest that shRNA design
should proceed according to the following steps:
1. Select the desired 21mer siRNA sequence using the most
current design rules.
2. Extend the above sequence towards the 3 0 end of the target,
for a duplex length of 25–29 bp.
3. Cap oﬀ the 3 0 end of the duplex (the bottom strand being
the guide strand) with a loop, preferably one derived from
a naturally occurring miRNA.
3.4. Inducible expression of RNAi eﬀectors
Constitutive knockdown of gene expression is not possible
when the target gene is essential. Clonal diﬀerences and other
counter-selection events occurring during the selection process
may also complicate the interpretation of results even in cases
when loss of target gene expression is not lethal. The above lim-
itations can be circumvented through inducible expression of
the RNAi eﬀector molecules. The last two years has seen a rapid
development of various methodologies for inducible expression
of shRNAs from polymerase III promoters. The ﬁrst method to
be described was based on the tetracycline-inducible system
[67]. A tetracycline-inducible H1 promoter was generated by
replacement of a 19 bp sequence between the TATA box and
the transcription start site with a binding site (tetO) for the tet-
racycline repressor [60]. In transgenic cells expressing the
repressor, repressor binding to the tetO site blocks transcrip-
tion, while addition of the inducer tetracycline or its derivative,
doxycycline, results in dissociation of the repressor, allowing
transcription to proceed. A similar strategy has been employed
to generate Tet-responsive U6 [57,68,69] and 7SK [57] promoter
based silencing vectors. Furthermore, replacement of a 26-nt se-
quence between the TATAbox and the transcription start site in
the H1 promoter with a lac operator, results in IPTG-respon-
sive shRNA expression in transgenic cells expressing the lac
repressor [70]. A major advantage of the above systems is
reversibility of knockdown. Thus, reemergence of target geneexpression has been demonstrated to occur within 3–4 days of
withdrawing the inducer for both doxycycline-inducible U6
[68] and lac-responsive [70] H1 expression systems. These doxy-
cycline-inducible expression systems are readily applicable
in vivo, as administration of non-toxic concentrations of doxy-
cycline in the drinking water of experimental animals results in
silencing of in vivo target gene expression [71].
The tet-responsive polymerase III promoters display some
level of leakiness, which may result in signiﬁcant downregula-
tion even in the absence of induction when working with very
potent shRNA [69] (Amarzguioui et al., unpublished data). A
more tightly regulated U6 promoter was recently described.
This expression system contains two optimally placed tet oper-
ators and displays a combination of low basal transcriptional
activity and eﬀective silencing in the induced state [69]. An
alternative to the tetracycline-inducible system is the more
tightly regulated but generally less active ecdysone-inducible
system [72]. Ecdysone (muristerone A)-inducible expression
of shRNA under a modiﬁed U6 promoter, in which the U6 en-
hancer was replaced with a GAL4 element, has been shown to
facilitate eﬃcient inducible silencing of target gene expression
in cells expressing a GAL4-Oct-2Q transactivator fusion and
the nuclear receptor/transcription factors VgEcR and RXR
[73]. Addition of the ecdysone analogue initiates an activation
cascade involving dimerization of the transgenic transcription
factors, activation of GAL4-Oct-2Q transactivator expression,
and ﬁnally, activation of the modiﬁed U6 promoter. shRNA-
mediated downregulation of gene expression was reversible,
as target gene expression recovered gradually from 2 to 4 days
after withdrawal of the inducer [73].
Recently, Cre-LoxP recombination based systems for condi-
tional shRNA-mediated downregulation of gene expression
have been reported [74–77]. This approach involves the inser-
tion of a loxP-ﬂanked stuﬀer sequence between the DSE and
PSE [76] or PSE and TATA box [75] elements within the U6
promoter to disrupt the proper spacing between these ele-
ments, thereby inactivating the promoter. Expression of the
Cre protein, either from an inducible endogenous locus [76]
or by exogenous lentiviral-mediated delivery [75], results in
recombination between the two loxP sites and removal of the
intervening stuﬀer sequence, which brings the diﬀerent ele-
ments of the promoter together, thereby generating an active
promoter. The disadvantage of the Cre-loxP system for condi-
tion expression compared to the other inducible systems is that
it involves genomic rearrangements, and is therefore irrevers-
ible. This system has substantial potential for in vivo spatio-
temporal control of gene expression, due to the existence of
a wide range of transgenic mouse strains expressing Cre in dif-
ferent tissue and at diﬀerent stages of development [78]. The
eﬀectiveness of this system in vivo has already been demon-
strated [77,79,80]. Especially encouraging is the demonstration
for the ﬁrst time of combined Cre recombinase and tetracy-
cline-dependent tissue-speciﬁc knockdown of gene expression
in transgenic mice carrying a Cre recombinase gene under
the control of a liver-speciﬁc tetracycline-responsive human
albumin promoter [79]. Liver-speciﬁc expression of Cre, result-
ing in activation of shRNA expression, could therefore be in-
duced simply by administration of the tetracycline-analogue
doxycycline in their feed. This approach in combination with
the many existing strains of Cre transgenic mice, will allow
the rapid development of conditional shRNA-expression
based mouse models for human genetic diseases.
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RNAi has emerged as one of the most interesting and
important mechanism for sequence-speciﬁc downregulation
of gene expression at both the transcriptional and post-tran-
scriptional levels. In essence, RNAi has enabled a number
of heretofore impossible genetic analyses to be conducted in
mammalian cell culture, and now in transgenic animals. The
explosion in the applications of RNAi for targeted gene
knockdown has fueled ingenious and very useful methodolo-
gies for design and delivery of small interfering RNAs and
their precursors, as well as siRNA or shRNA gene expression
units. Aside from widespread applications in gene analyses
and target validation in mammalian cells and experimental
animals, RNAi is emerging as a potential therapeutic modal-
ity as well. Of utmost importance is the fact that a major per-
centage of the human transcriptome is proposed to be
regulated post-transcriptionally by miRNAs. A better under-
standing of this important epigenetic process will certainly
translate into more eﬃcacious siRNA experiments and appli-
cations. The recent discovery of transcriptional gene silencing
mediated by small RNAs also will open many new possibili-
ties for modulating gene expression in mammalian systems.
Those of us studying the mechanisms and applications of
RNAi all have the feeling that there are many more exciting
discoveries and applications of small RNAs yet to come.
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